Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Therapeutics and Clinical Risk Management|May 14, 2008
Reflections on adjuvant treatment of gastric cancerAlbert Abad, José Luis Manzano, Cristina Martí
Investigational New Drugs|August 5, 2004
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell linesCarmen Plasencia, Albert Abad, Eva Martinez-Balibrea, et al.
Cancer Metastasis Reviews|February 12, 2011
Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumorsJaume Capdevila, Ramón Salazar, Irene Halperín, et al.
The Journal of Liquid Biopsy|March 3, 2025
Liquid biopsy, big data and artificial intelligence as a new global clinical trial model in targeted therapyAlbert Abad, Joana Vidal, Laura Layos, et al.
Pharmacogenomics|November 20, 2002
Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancerCarme Sarries, Eric B Haura, Barbara Roig, et al.
Oncology Reports|February 3, 2007
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecanEva Martinez-Balibrea, Jose Luis Manzano, Anna Martinez-Cardus, et al.
Anti-Cancer Drugs|March 22, 2006
UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumorsJavier Sastre, Enrique Aranda, Albert Abad, et al.
Molecular Cancer Therapeutics|April 18, 2009
A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell linesEva Martinez-Balibrea, Carmen Plasencia, Alba Ginés, et al.
International Journal of Cancer|March 20, 2009
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapyEva Martinez-Balibrea, Anna Martínez-Cardús, Eva Musulén, et al.
Anti-Cancer Drugs|May 29, 2004
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumorsAlbert Abad, Bartomeu Massutí, Javier Gallego, et al.
Pageof 4